# Nine-month interim report (Q3) 2026 (unaudited)

- Published: 2026-11-17
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/nine-month-interim-report-q3-2026-unaudited/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

**ALK delivers 15% organic revenue growth with an operating profit (EBIT) margin of 27% in Q3**

ALK delivered 15% organic revenue growth in Q3, driven by tablet sales, which grew by 35%, with solid growth across sales regions. Operating profit increased by 9% with an EBIT margin of 27% in the quarter and 28% for the first nine months. The full-year outlook, upgraded on 7 October 2026, has been confirmed.

**Performance highlights** **(Q3)**

*Comparative figures for Q3 2025 are shown in brackets. G**rowth rates are stated in local currencies (l.c.), unless otherwise indicated.*

-   Revenue increased by 15% to DKK 1,764 million (1,530), driven by tablet sales.
-   Tablet sales grew by 35% to DKK 999 million (737), supported by the paediatric roll-out, with 33% growth in Europe, 32% in North America and 47% in International markets.
-   SCIT/SLIT drop sales decreased by 6% to DKK 527 million (557), impacted by lower SCIT shipments to China.
-   Sales of Anaphylaxis & other products increased by 1% to DKK 238 million (236). In isolation, anaphylaxis sales increased by 5%.
-   Operating profit (EBIT) increased by 9% to DKK 469 million (423) with an EBIT margin of 27% (28%).
-   Free cash flow was DKK 303 million (290). For the first nine months it increased to DKK 1,192 million (836).
-   The net debt to EBITDA ratio was negative at 0.7 at the end of September 2026.  
      
    

**Financial highlights**

<table><tbody><tr><td><b>&nbsp;</b></td><td colspan="3"><b>&nbsp;</b></td><td colspan="3"><b>Growth</b></td><td colspan="4"><b>&nbsp;</b></td><td colspan="3"><b>Growth</b></td></tr><tr><td>In DKKm</td><td colspan="2"><b>Q3 2026</b></td><td colspan="3"><b>l.c.</b></td><td><b>r.c.</b></td><td colspan="3"><b>9M 2026</b></td><td colspan="3"><b>l.c.</b></td><td><b>r.c.</b></td></tr><tr><td><b>Revenue</b></td><td colspan="2"><b>1,764</b></td><td colspan="3"><b>15%</b></td><td><b>15%</b></td><td colspan="3"><b>5,330</b></td><td colspan="3"><b>17%</b></td><td><b>16%</b></td></tr><tr><td><b>EBIT</b></td><td colspan="2"><b>469</b></td><td colspan="3"><b>9%</b></td><td><b>11%</b></td><td colspan="3"><b>1,484</b></td><td colspan="3"><b>16%</b></td><td><b>17%</b></td></tr><tr><td><b>EBIT margin </b>–<b> %</b></td><td colspan="2"><b>27%</b></td><td colspan="3"><b>&nbsp;</b></td><td><b>&nbsp;</b></td><td colspan="3"><b>28%</b></td><td colspan="3">&nbsp;</td><td>&nbsp;</td></tr><tr><td colspan="14">l.c.: local currency; r.c.: reported currency</td></tr></tbody></table>

**Allergy+ strategy highlights**

-   ALK and its Chinese partner GenSci expects to file for regulatory approval of the house dust mite tablet ACARIZAX® in China in H1 2027, based on the recent successful outcome of a phase 3 clinical trial.
-   *neffy®* nasal adrenaline spray (2 mg) launched in 14 markets at the end of September. The recent launch in Canada and the 1 mg launch for young children in Germany are progressing well.
-   ALK has entered into a partnership with Zuellig Pharma for select Southeast Asian markets, under which Zuellig will sub-license *neffy®* from ALK.
-   ALK has expanded its partnership with Catalent to secure long-term access to the Zydis® tablet technology formulation and increase annual tablet manufacturing capacity to 1.1 billion from the early 2030s.
-   ALK has submitted a clinical trial application to the US Food and Drug Administration (FDA) and is currently awaiting feedback from the authorities on the peanut allergy tablet phase 3 development plans before initiating the trial.

**2026 full-year outlook confirmed**

The full-year financial outlook was upgraded on 7 October 2026 (reference is made to Company Release 16/2026), reflecting a strong growth momentum in tablet sales across regions. This outlook has been confirmed.

-   Revenue is expected to grow by 16-17% in local currencies, based on growth across all sales regions and product lines with tablets as the key driver of growth.
-   The EBIT margin is expected at around 27%, mainly reflecting operating leverage from the revenue growth.  
      
    

**Commenting on the Q3 results, CEO Peter Halling said:** *“ALK’s 35% tablet growth in Q3 reflects the strength of our strategy, and paediatric use is increasingly contributing to the growth. We are very pleased that the phase 3 trial with ACARIZAX® in China met its primary objective opening up a new important opportunity, and the expanded partnership with Catalent strengthens our long-term tablet supply. Together with the upgraded outlook, this reinforces our confidence in our ability to reach more patients with evidence-based allergy and anaphylaxis solutions."*

**Hørsholm, 17 November 2026**

**ALK-Abelló A/S**

**For further information, contact:**  
*Investor Relations*: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525  
*Media:* Maiken Riise Andersen, tel. +45 5054 1434

*ALK is hosting a conference call for analysts and investors today at* ***3.30*** *p.m. (CET) at which Management will review the financial results and the outlook. The conference call will be audio cast on* <a href="https://www.globenewswire.com/Tracker?data=OUI1pyB0Y_QwkHIeTSMWCYhPmVIkH-j_5MazAtkqnHSjtRVBi9xZCPDU-k5l3TWeKVrCnex4FzNyUvyyDd3-Kh_ne5OAuPSrchTwrP5tV9c=" rel="nofollow">*https://ir.alk.net*</a> *where the relevant presentation will be available shortly before the call begins.*

*To register for the conference call, please use this* <a href="https://www.globenewswire.com/Tracker?data=hagna03QLkFkRqkt99xSklg4Vj7kuqMCkqOO5Uz8--EQjWiZQ4vwthCTjUeZiznaCe6v6pbT60_cZQrqPPu48_4sVbaaQsTlJ5oopshmW8gn_uJ6cYlh0lUStyVPL12V" rel="nofollow">*link*</a> *and follow the registration instructions. You will receive an email from diamondpass@choruscall.com with dial-in details, including a passcode and a pin code. Please make sure to whitelist diamondpass@choruscall.com and/or check your spam filter. We advise you to register well in advance and to call in before* ***3.25*** *p.m. (CET).*

**Attachment**

-   <a href="https://www.globenewswire.com/Tracker?data=9wHRQSSMf-pnGtsBU5RTzbqNoCqU3lvdoujwHP0bHzoSa0-LVA4UgseJZ61dFHn8DVKk1rK9sPu8DXGJA3pwHInuwQrZ2v5UNd7paeDd-xbukNP8dJdcGrfwd7hqu_ZQ0ZFuMrDRQY-eZbGwEyGm58SnW6GLijm99a6zSELOgfsjCT6f3h279KPj37Bp2VgBfHXbmIWiRfP-InG-sEySEg==" rel="nofollow">Company release\_19\_26UK\_171126\_Q3 26 interim report</a>

  
![](https://ml-eu.globenewswire.com/media/OTdlYWE1MDItZmMyYi00ZjYzLTg0NjYtZjA2YTJiZGY0ZWQ5LTEwMTM4MDQtMjAyNi0xMS0xNy1lbg==/tiny/ALK-Abello.png)
